https://www.fiercebiotech.com/ en https://www.fiercebiotech.com/venture-capital/top-line-top-money-raisers-biotech This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. Mar 28, 2024 12:43pm Ayla Ellison, Max Bayer, Annalee Armstrong https://www.fiercebiotech.com/28d1b8d2-7723-4bfe-b0c6-e5a82a76f92d https://www.fiercebiotech.com/venture-capital/parkinson-s-nonprofit-founds-virtual-single-asset-biotech Nonprofit Parkinson’s UK has teamed up with the University of Sheffield to create a virtual biotech. The single-asset startup will work with service providers to advance an Nrf2 inhibitor toward the clinic. Mar 9, 2017 9:33am Nick Paul Taylor https://www.fiercebiotech.com/9d5cb835-3f25-4aaf-81c9-0b17340272ac https://www.fiercebiotech.com/venture-capital/hospital-group-invests-20m-stem-cell-therapy-biotech Hospital group Sanford Health has invested $20 million in InGeneron to support clinical trials of a stem cell regenerative medicine. The Series D gives Sanford a financial stake in an adipose-derived stem cell therapy it is testing in a clinical trial at its network of healthcare facilities. Mar 6, 2017 8:40am Nick Paul Taylor https://www.fiercebiotech.com/ae469346-c5ba-44b3-be37-0ea70ee7f76c https://www.fiercebiotech.com/venture-capital/arix-takeda-team-up-to-build-oncology-gi-biotechs Arix Bioscience has teamed up with Takeda Ventures to create and grow biotechs. The agreement gives Arix another outlet for turning promising research into biotech startups, and Takeda access to the deal flow provided by the network its new partner has put together. Mar 2, 2017 4:53am Nick Paul Taylor https://www.fiercebiotech.com/b158773c-c25b-4f27-91c6-447b42a77f59 https://www.fiercebiotech.com/venture-capital/pharma-two-b-raises-30m-for-parkinson-s-phase-3-from-biogen-backed-fund-adds-ex Pharma Two B has raised $30 million (€28 million) to complete a phase 3 trial of its Parkinson’s asset P2B001. The round provides a hint of the impact of the recently founded Israel Biotech Fund, which led the investment and is adding ex-Pfizer CEO Jeff Kindler to Pharma Two B’s board. Feb 27, 2017 7:37am Nick Paul Taylor https://www.fiercebiotech.com/51f9a002-aba4-4cec-86a3-f47b05ad7c75 https://www.fiercebiotech.com/venture-capital/j-j-leads-25m-series-a-targeted-radiotherapy-startup Johnson & Johnson Innovation has led a $25 million Series A in targeted cancer radiotherapeutic startup Fusion Pharmaceuticals. The funding will support a phase 1a of Fusion’s antibody-targeted radiotherapy, beyond which the Canadian biotech plans to run a proof-of-concept trial in non-small cell lung cancer. Feb 24, 2017 3:27am Nick Paul Taylor https://www.fiercebiotech.com/5b6bfb95-5469-4e76-989b-7f62bb39de2a https://www.fiercebiotech.com/biotech/british-life-sciences-investment-firm-arix-bioscience-hits-ps100m-ipo-target Arix Biosciences has made good on its promise to raise £100 million ($127 million) in its public offering on the London Stock Exchange as it looks to put the new funds to use in investments across as many as 15 early-stage biotechs. Feb 17, 2017 5:02am Ben Adams https://www.fiercebiotech.com/d2b52023-0a1a-4256-abc3-89ca4832659b https://www.fiercebiotech.com/venture-capital/vc-backed-public-offerings-at-lowest-ebb-since-2011 Six venture-backed IPOs raised just $574.5 million in the first quarter of 2016, according to the Exit Poll Report, marking the slowest quarter for these types of offerings in nearly 5 years. Apr 4, 2016 10:37am Ben Adams https://www.fiercebiotech.com/8d5ad9d8-2b7b-48b6-8258-4032bf96723d https://www.fiercebiotech.com/venture-capital/a-listers-provide-a-50m-b-round-to-astrazeneca-s-antibiotics-spinout-entasis Last summer, AstraZeneca formally spun out its pared-down early-stage antibiotics unit in Waltham, MA, as Entasis Therapeutics, bequeathing a $40 million A round for a launch after it failed to find a buyer for the group. Today, the company gained another $50 million in venture backing from some A-list investors. Apr 4, 2016 9:51am John Carroll https://www.fiercebiotech.com/c5b30334-222c-4bee-bf6d-0d1cd39bb3ff https://www.fiercebiotech.com/venture-capital/analysts-warn-of-a-bust-biotech-space-as-nasdaq-biotech-index-falls-23 The fallout from Valeant is radiating into the biotech sphere as the industry's stock continues to burn. Apr 1, 2016 3:39am Ben Adams https://www.fiercebiotech.com/9cdfbb6c-a072-43c0-b46a-7ead9a0c53db https://www.fiercebiotech.com/venture-capital/updated-quanterix-raises-46m-series-d-round Molecule testing and diagnostics firm Quanterix Corporation has secured $46 million in Series D funding from both new and existing investors, adding to the $54 million it's raised in previous rounds. Mar 23, 2016 10:50am Ben Adams https://www.fiercebiotech.com/a3c5ae76-fdf2-48d6-ba72-5687484d6b50 https://www.fiercebiotech.com/venture-capital/early-stage-biotech-funding-at-risk-from-drying-well Funding streams for early-stage biopharma and med tech research dwindled in 2015, as investors shifted their support to bigger companies--potentially cutting off the lifeblood for future life sciences R&D. Mar 16, 2016 12:17pm Ben Adams https://www.fiercebiotech.com/f4b383fb-2cda-474e-808b-4257c77134f4 https://www.fiercebiotech.com/venture-capital/tizona-therapeutics-inc-completes-43-million-series-b-financing Proceeds will be Used to Advance Company's Immunotherapy Programs SOUTH SAN FRANCISCO Calif., March 8, 2016 -- Tizona Therapeutics, Inc., a privately held immunology company harnessing the power... Mar 8, 2016 7:30am https://www.fiercebiotech.com/ca25079c-89fe-4cf5-a196-1f1ead1a3f03 https://www.fiercebiotech.com/venture-capital/autolus-fundraising-now-tops-105m-for-next-gen-car-t-work A little more than a year after nailing down a $45 million launch round, Neil Woodford has joined in a $60 million follow-up raise for Autolus aimed at accelerating its research into next-gen CAR-T drugs. Mar 3, 2016 2:30pm John Carroll https://www.fiercebiotech.com/6ef7aad4-0887-48c6-b822-134dd118453c https://www.fiercebiotech.com/venture-capital/savara-raises-20m-to-push-its-inhaled-antibiotic-into-phase-iii Austin, TX, biotech Savara Pharmaceuticals picked up $20 million in Series C cash as it moves toward Phase III with an inhaled antibiotic designed to combat infections in patients with cystic fibrosis. Mar 1, 2016 10:06am Damian Garde https://www.fiercebiotech.com/315b377f-f62d-4122-bd95-fed6554ea200 https://www.fiercebiotech.com/venture-capital/israel-s-polypid-raises-22m-after-a-couple-of-failed-ipo-attempts Israeli drug developer PolyPid is moving on from a pair of IPO misfires, raising $22 million in venture financing to advance its pipeline of antibiotic treatments. Feb 24, 2016 8:01am Damian Garde https://www.fiercebiotech.com/93f77ff9-02ba-4c5c-856b-4f3d01c05534 https://www.fiercebiotech.com/venture-capital/new-canadian-biotech-aims-for-a-novel-approach-to-blood-cancer-rare-disease A new Toronto startup has burst into life this week as it announces two "transformative" ex vivo gene therapies to tackle both blood cancer and a hereditary disorder. Feb 19, 2016 10:45am https://www.fiercebiotech.com/7f21d54e-a878-4604-b9e8-5f9dcc028a93 https://www.fiercebiotech.com/venture-capital/cancer-biotech-effector-pockets-16m-to-back-its-lead-drug San Diego's eFFECTOR Therapeutics boosted its B round by $16 million, stockpiling cash as it mounts clinical trials for a cancer therapy. Feb 19, 2016 10:01am Damian Garde https://www.fiercebiotech.com/1b0cec1e-07d4-43eb-ac41-6ddb18dcf2cd https://www.fiercebiotech.com/venture-capital/apellis-raises-47m-after-pulling-plug-on-an-86m-ipo Louisville, KY, drug developer Apellis Pharmaceuticals raised $47.1 million in venture cash to push its pipeline of treatments for rare diseases, regrouping after aborting an effort to go public earlier this month. Feb 12, 2016 8:41am Damian Garde https://www.fiercebiotech.com/a1c50c14-9762-40f9-9017-c75cbf52373d https://www.fiercebiotech.com/venture-capital/biogen-sanofi-back-tony-coles-neurodegeneration-player-yumanity For much of 2015, Tony Coles funded his neurodegeneration-focused startup Yumanity out of his own pocket. Seed money followed. And today he's pulling the veils off a $45 million A round designed to get him through the preclinical stage of identifying his top programs and on the way to further enlivening a growing field. Feb 10, 2016 12:00am John Carroll https://www.fiercebiotech.com/c6d486e4-1c6f-42ad-8265-e02e0c00ddd4 https://www.fiercebiotech.com/venture-capital/amplyx-ups-its-b-round-to-49-2m-on-way-to-clinical-an-antifungal-drug San Diego's Amplyx Pharmaceuticals boosted its Series B fundraise to $49.2 million and expanded its executive ranks, on pace to take its lead antifungal treatment into human trials this year. Feb 9, 2016 9:34am Damian Garde https://www.fiercebiotech.com/39c1bcca-9ad9-4a2a-a552-a604ebc2b2ef https://www.fiercebiotech.com/venture-capital/backed-by-a-lineup-of-marquee-vcs-unity-biotechnology-tackles-hard-science-of-aging Imagine a drug that could clear away "senescent" cells and make the life span allotted to you healthier, absent many of the myriad diseases that can accumulate with age. Some investigators have been working on that subject for more than a decade, and now a biotech is being launched to see if it can make that dream a reality. Feb 3, 2016 2:18pm John Carroll https://www.fiercebiotech.com/faa849f8-086c-4355-87c3-2361ee40e797 https://www.fiercebiotech.com/venture-capital/updated-enyo-pharma-gets-a-24m-funding-boost-for-hep-b-cure-candidate The new French biotech Enyo Pharma has raised a good chunk of money in its first round of financing as it looks to start human testing for a potential hepatitis B cure. Feb 3, 2016 7:19am https://www.fiercebiotech.com/f01a3fd2-b360-47f0-a0ee-3ece30f3c8af https://www.fiercebiotech.com/venture-capital/glaxo-atlas-syndicate-bankrolls-spero-s-drive-into-clinic-30m-round Eight months after wrapping its first venture round with a $30 million bankroll, Cambridge, MA-based Spero Therapeutics has gone back to the well for $30 million more. Feb 2, 2016 7:32am John Carroll https://www.fiercebiotech.com/8aa99136-fe83-4e6e-8ad7-17e4de6eb7cd https://www.fiercebiotech.com/venture-capital/backed-by-j-j-and-glaxo-veteran-vc-group-splits-from-index-unveils-227m-fund The biotech team at Index Ventures is splitting away to focus exclusively on what they do best: jump-starting new therapeutic programs in Europe. Feb 1, 2016 4:39pm John Carroll https://www.fiercebiotech.com/a219fb42-c470-4cc9-a6bc-36206290b747